CALC
CalciMedica, Inc. NASDAQ Listed Jun 14, 2023$1.75
After hrs
$1.75
+0.00%
Mkt Cap $5.5M
52w Low $1.63
0.3% of range
52w High $36.00
50d MA $2.90
200d MA $7.44
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-1.5x
ROE
445.1%
P/FCF
-1.3x
RSI (14)
27.90
ATR (14)
$0.16
Beta
1.09
50d MA
$2.90
200d MA
$7.44
Avg Volume
159.6K
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
505 Coast Boulevard South · La Jolla, CA 92037 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | AMC | -0.28 | -0.45 | -57.9% | 0.66 | +0.3% | -5.7% | +6.0% | +2.7% | -1.9% | -3.7% | — |
| May 12, 2026 | AMC | -0.28 | -0.30 | -7.1% | 0.63 | -2.7% | +9.5% | -1.4% | -3.4% | -5.6% | -0.4% | — |
| Mar 3, 2026 | AMC | -0.55 | -0.32 | +41.8% | 0.58 | +1.7% | +7.5% | +5.9% | +10.0% | +0.6% | -7.7% | — |
| Nov 12, 2025 | AMC | -0.41 | -0.39 | +4.9% | 3.34 | -2.7% | -3.3% | -7.1% | +4.7% | -2.2% | +2.9% | — |
| Aug 12, 2025 | AMC | -0.40 | -0.40 | +0.0% | 2.48 | +10.5% | -4.4% | +10.1% | +11.5% | +1.0% | -5.4% | — |
| May 14, 2025 | AMC | -0.43 | -0.36 | +16.3% | 1.91 | +4.2% | +1.6% | +3.1% | -7.0% | +0.0% | -5.9% | — |
| Mar 27, 2025 | AMC | -0.48 | -0.34 | +29.2% | 2.07 | +0.0% | -3.9% | -4.0% | +2.1% | -5.1% | -1.1% | — |
| Nov 13, 2024 | AMC | -0.61 | -0.50 | +18.0% | 3.40 | -1.5% | -0.9% | -1.2% | +1.5% | -0.9% | +3.0% | — |
| Aug 12, 2024 | AMC | -0.55 | -0.52 | +5.5% | 4.68 | -0.4% | -3.6% | +0.4% | -9.5% | +2.2% | +0.2% | — |
| May 13, 2024 | AMC | -0.50 | -0.43 | +14.0% | 5.20 | -2.5% | +6.7% | -1.3% | -0.9% | +0.4% | -0.9% | — |
| Mar 28, 2024 | AMC | -1.00 | -0.23 | +77.0% | 4.16 | +1.0% | -5.5% | +2.8% | +3.6% | +3.9% | -1.3% | — |
| Nov 9, 2023 | AMC | -1.14 | -0.82 | +28.1% | 3.15 | +3.2% | +7.1% | +0.8% | -0.1% | +3.2% | -4.1% | — |
| Aug 10, 2023 | AMC | -1.02 | -1.11 | -8.8% | 3.28 | +0.0% | -0.4% | -2.1% | +1.6% | -1.4% | +1.7% | — |
| May 12, 2023 | AMC | -0.73 | -23.43 | -3109.6% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 20 | Guggenheim | Initiates | Buy | $9 | $0.61 | $0.62 | +0.5% | -4.9% | -1.8% | -2.9% | +5.7% | -0.1% |
| Mar 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.62 | $0.61 | -2.0% | +5.9% | +10.0% | +0.6% | -7.7% | +2.5% |
| Jan 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.25 | $1.13 | -9.6% | -18.4% | -11.8% | -25.6% | -9.1% | +8.4% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.91 | $1.99 | +4.2% | +1.6% | +3.1% | -7.0% | +0.0% | -5.9% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.91 | $2.00 | +4.7% | +2.1% | -5.1% | -1.1% | -0.5% | -0.5% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.07 | -5.9% | +3.2% | -6.2% | +3.3% | +1.8% | -3.1% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.40 | $3.35 | -1.5% | -0.9% | -1.2% | +1.5% | -0.9% | +3.0% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.51 | $3.69 | +5.1% | -0.3% | +1.1% | -1.1% | +0.0% | -0.9% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $4.66 | -0.4% | -3.6% | +0.4% | -9.5% | +2.2% | +0.2% |
| Jul 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.44 | $4.47 | +0.7% | +3.2% | +3.1% | +3.6% | -1.6% | +1.5% |
| Jul 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.25 | $4.30 | +1.2% | +4.5% | +3.2% | +3.1% | +3.6% | -1.6% |
| Jun 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.66 | $3.87 | -17.0% | -32.4% | +25.7% | +7.3% | -5.6% | +6.2% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.20 | $5.07 | -2.5% | +6.7% | -1.3% | -0.9% | +0.4% | -0.9% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.20 | +1.0% | -5.5% | +2.8% | +3.6% | +3.9% | -1.3% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.16 | $4.20 | +1.0% | -5.5% | +2.8% | +3.6% | +3.9% | -1.3% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.39 | -2.4% | -3.6% | +0.5% | -9.6% | -8.6% | -5.8% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.70 | $5.75 | +0.9% | -8.2% | -7.3% | -7.0% | -0.4% | -2.9% |
| Nov 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.37 | $3.21 | -4.8% | +0.8% | -0.0% | +3.2% | -4.1% | +3.6% |
| Jul 7 | EF Hutton | Maintains | Buy → Buy | — | $4.00 | $3.88 | -3.0% | -3.5% | -4.4% | -2.4% | +7.1% | -4.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Middleton Fred A | — | Buy | 248,972 | $0.80 | $200K | 1,063,272 | +4.36% | -3.25% |
8-K
CalciMedica, Inc. -- 8-K Filing
Sep 2
8-K
CalciMedica, Inc. -- 8-K Filing
Aug 27
8-K
CalciMedica, Inc. -- 8-K Filing
Aug 20
8-K · 2.02
!! High
CalciMedica, Inc. -- 8-K 2.02: Earnings Results
Aug 11
8-K · 3.02
!! High
CalciMedica, Inc. -- 8-K 3.02: Unregistered Securities Offering
Jun 24
8-K
CalciMedica, Inc. -- 8-K Filing
Jun 24
8-K · 2.02
!! High
CalciMedica, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K
Unknown — 8-K Filing
CALC risks Nasdaq delisting if market capitalization doesn't exceed $35 million for 10 consecutive days within 180 days, threatening liquidity and investor confidence.
Mar 18
8-K
CalciMedica, Inc. -- 8-K Filing
CalciMedica reported 2025 financial results and provided clinical updates on its CRAC channel inhibitor programs, including progress in acute kidney injury trials.
Mar 3
Institutional (13F) — Top 19
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Meritage Portfolio Management | 61,539 | $406K | — | Dec 2025 |
| 2 | L1 Global Manager Pty Ltd | 248,972 | $256K | New | Jun 2026 |
| 3 | Jane Street Group, Llc | 19,203 | $127K | New | Dec 2025 |
| 4 | Cambridge Investment Research Advisors, Inc. | 120,000 | $124K | New | Jun 2026 |
| 5 | Renaissance Technologies Llc | 97,300 | $100K | Reduced | Jun 2026 |
| 6 | Vanguard Capital Management Llc | 88,956 | $92K | Reduced | Jun 2026 |
| 7 | 180 Wealth Advisors, Llc | 83,400 | $86K | Reduced | Jun 2026 |
| 8 | Hrt Financial Lp | 39,699 | $21K | New | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 30,716 | $17K | New | Mar 2026 |
| 10 | Tritonpoint Partners, Llc | 15,119 | $16K | — | Jun 2026 |
| 11 | Sound View Wealth Advisors Group, Llc | 10,000 | $10K | Reduced | Jun 2026 |
| 12 | Simplex Trading, Llc | 12,816 | $7K | New | Mar 2026 |
| 13 | Northern Trust Corp | 12,530 | $7K | — | Mar 2026 |
| 14 | Rockefeller Capital Management L.p. | 5,000 | $3K | Reduced | Mar 2026 |
| 15 | Brown Brothers Harriman & Co | 308 | $166 | — | Mar 2026 |
| 16 | Sbi Securities Co., Ltd. | 87 | $90 | New | Jun 2026 |
| 17 | Ubs Group Ag | 17 | $9 | Reduced | Mar 2026 |
| 18 | Wells Fargo & Company/mn | 10 | $5 | New | Mar 2026 |
| 19 | Bnp Paribas Financial Markets | 3 | $2 | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 46,661 | $24K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 12,421 | $10K | May 2026 |
| 3 | Fidelity Total Market Index Fund | 11,686 | $10K | May 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 9,699 | $5K | Feb 2026 |
Valuation
Market Cap
$5.5M
Enterprise Value
$22.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-54.43x
P/B
—
P/S
—
P/FCF
-1.27x
EV/EBITDA
—
Shares Out
15.8M
Financials (TTM)
Revenue
$0
Net Income
-$21.2M
EBITDA
-$19.9M
Free Cash Flow
-$21.2M
Op Cash Flow
-$21.2M
EPS Basic
$-1.97
EPS Diluted
$-6.95
EPS Forward
$-1.34
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$13.6M
Total Liab.
$20.2M
Total Equity
-$6.6M
Cash
$13.0M
LT Debt
$8.4M
Book Value/Sh
$-0.00
Debt/Equity
-1.46x
Current Ratio
3.58
Quick Ratio
3.58
Returns & Growth
ROE
445.1%
ROA
-217.5%
ROIC
-209.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
-61.5%
Price Returns
2W
-19.3%
1M
-40.8%
3M
-44.4%
6M
-39.6%
12M
-88.4%
Technicals
52W High
$36.00
52W Low
$1.63
50d MA
$2.90
200d MA
$7.44
RSI (14)
27.90
ATR (14)
$0.16
Beta
1.09
Avg Volume
160K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$266.00
High
$392.00
Low
$14.00
Median
$392.00
Data updated apr 24, 2026 11:43pm
· Source: financialmodelingprep.com